SCHEMBL3246435

SCHEMBL3246435

Cc1cc(C)cc(S(=O)(=O)NCC(=O)Nc2ccc(Cl)cc2C(O)c2ccccc2Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
BACE1 P56817 1/20 0.41
LMNA P02545 6/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HTT P42858 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
FDFT1 P37268 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247544 0.90 ALDH1A1 (0.48) ALDH1A1LMNATSHRMAPTMEN1
SCHEMBL3249174 0.89 L3MBTL1 (0.44) ALDH1A1BACE1LMNAMAPK1MAPT
SCHEMBL3244695 0.88 CYP1A2 (0.48) ALDH1A1LMNATSHRMAPTMEN1
SCHEMBL3253240 0.87 ALDH1A1 (0.46) ALDH1A1LMNATSHRMAPTMEN1
SCHEMBL3253080 0.86 FDFT1 (0.40) ALDH1A1BACE1LMNAMAPTMEN1
SCHEMBL3251156 0.86 FLT1 (0.42) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL3251363 0.86 SMN1; SMN2 (0.43) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL4869106 0.86 TSHR (0.47) ALDH1A1LMNAMAPK1TSHRMAPT
SCHEMBL3250956 0.85 CTSS (0.47) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL3249667 0.85 FDFT1 (0.39) ALDH1A1BACE1LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 ALDH1A1 2179/4885BACE1 529/4885LMNA 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.